Remarkably, most of the reductions in anchorage-independent growth (Fig. 4b, c) and xenograft tumor growth (Fig. 4d) induced by the combination were found to require DLC1 expression, strongly implying that DLC1 protein makes a critical contribution to the growth inhibition observed with the three-drug combination. The gene discussed is DLC1; the disease is neoplasm.